Cytosorbents Corporation
CTSO
$0.61
$0.023.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 60.43% | 47.95% | 62.27% | 42.49% | 29.16% |
| Total Depreciation and Amortization | -6.48% | -20.74% | -20.68% | -20.77% | -13.81% |
| Total Amortization of Deferred Charges | 115.22% | 301.05% | -- | -- | -- |
| Total Other Non-Cash Items | -165.54% | -155.62% | -149.44% | -20.23% | 192.73% |
| Change in Net Operating Assets | 76.48% | 60.00% | 123.77% | -30.27% | -265.30% |
| Cash from Operations | 14.22% | 46.51% | 53.95% | 44.12% | 33.37% |
| Capital Expenditure | 42.25% | 59.74% | 13.59% | -226.87% | 47.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.06% | 66.79% | -0.97% | -13.56% | 3.29% |
| Cash from Investing | 37.97% | 63.58% | 5.88% | -54.93% | 28.54% |
| Total Debt Issued | -83.48% | -100.00% | -100.00% | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | -600.00% | -- |
| Issuance of Common Stock | 3,002.68% | -42.93% | -45.79% | -49.44% | -98.48% |
| Repurchase of Common Stock | 97.33% | 97.33% | -20,950.00% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 92.66% | -- | -- |
| Cash from Financing | -0.24% | -67.26% | -68.81% | 26.61% | -35.53% |
| Foreign Exchange rate Adjustments | 1,852.94% | 142.53% | 289.25% | 38.01% | 14.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 65.94% | -246.59% | -3,161.85% | 128.35% | 28.79% |